Overture Life Expands Global Footprint with UAE Launch, Partnering with Emitac Healthcare Solutions to Bring Automated IVF to the Gulf
Following Launches in Brazil and India, UAE Becomes Overture's First Middle East Market and the Latest Anchor in the Global Shift Toward Automated Embryology
Overture Life, a leading developer of automated IVF technologies and the first company to achieve live births from both robotic fertilization and robotic egg freezing, today announced a strategic partnership with Emitac Healthcare Solutions, a leading distributor of advanced medical and laboratory technologies in the UAE, Saudi Arabia, Oman, and pan-Africa, to bring the DaVitri automated IVF laboratory platform to fertility clinics across the country. The UAE launch follows Overture's recent market entries in Brazil and India, establishing the company's first foothold in the Middle East and reinforcing the rapid global expansion of automated embryology across the world's highest-volume fertility markets.
DaVitri, cleared by the UAE Ministry of Health and Prevention (MOHAP), with regulatory work already underway in Saudi Arabia and Oman, automates vitrification through a regulated, microfluidic system. The platform reduces the operator-dependent variability that has long constrained procedural consistency in embryology. With clearances now in place across the United States, Europe, South America, and the UAE, DaVitri has become the most broadly authorized automated IVF platform in the world. The pattern reflects a deliberate focus on the world's highest-volume fertility markets, where patient demand, clinical ambition, and pressure for reproducible outcomes are converging at the same moment automation has become clinically and commercially viable.
